Trial NCT01468311

View at ClinicalTrials.gov 
Org. Study IDs: 120003
Secondary IDs: 12-C-0003

Last trial update was posted on 2021-10-06

MeSH Interventions

Daclizumab

MeSH Conditions

Hodgkin Disease Lymphoma

Other Conditions

Hodgkin Lymphoma

Stopping Reasons

Poor enrollment and ability to radioconjugate Daclizumab. Neither Center for Cancer Research (CCR) or Nuclear Medicine/Radiology wanted to do the facilities upgrade and hire personnel needed to radioconjugate the drug at the Clinical Center.

Limitations And Caveats

N/A

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID